Decline of Serum HBV DNA and No Change Apportioned by the Same Hepatic Parenchyma Cell Volume from Hepatic Fibrosis Stage 1 to Stage 4 during the Natural History of Chronic Hepatitis B

Abstract

During the initial phase of chronic hepatitis B virus (HBV) infection, serum HBV DNA levels are high. Contrarily, fibrosis, cirrhosis and hepatocellular carcinoma have been found in patients with lower serum HBV DNA levels. The aim of this study is to clarify HBV DNA level dynamics of serum apportioned by the same hepatic parenchyma cell volume (HPCV) in hepatic fibrosis stages 1–4 during the natural history of chronic hepatitis B. Serum HBV DNA levels were evaluated by real-time polymerase chain reaction. Further, serum HBV DNA levels were apportioned by and compared with the same HPCV in hepatic fibrosis stages 1–4, respectively. Serum HBV DNA levels were 8.91 × 10⁶ ± 4.37 × 10¹, 8.13 × 10⁶ ± 7.41 × 10¹, 9.55 × 10⁵ ± 1.02 × 10², and 4.07 × 10⁵ ± 7.24 × 10¹ copies/ml, respectively; there were differences among hepatic fibrosis stages 1–4 (p < 0.021–0.000). However, serum HBV DNA levels apportioned by the same volume of hepatic parenchyma cells in hepatic fibrosis stages 1–4 were 3.47 × 10¹⁰ ± 8.71 × 10², 1.02 × 10¹¹ ± 9.55 × 10², 1.41 × 10¹⁰ ± 2.57 × 10³, and 3.72 × 10¹⁰ ± 3.02 × 10³ with HPCV proportions 65.9, 62.7, 58.9, and 53.3%, respectively; there were no differences among hepatic fibrosis stages 1–4 (p > 0.203–0.967).Following the progression of hepatic fibrosis from stage 1 to 4, ongoing decline of HPCV is responsible for a declining trend of serum HBV DNA levels.

Hepatitis C virus load in parenchyma cells correlates with hepatic injury in infected patients

“…As hepatic fibrosis progresses, the liver parenchyma cell volume decreases and can cause changes in viral loads. Previous studies have reported that the severity of hepatic injury is not consistent with the serum HCV load in HCV-infected patients (12,13). Therefore, it can be hypothesized that hepatic injury is associated with the HCV load in the parenchyma cells of HCV-infected patients.…”

Antitumor effect of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles on mice bearing breast cancer: a systemic toxicity assay

“…Morphometric analysis was also carried out to verify the percentage of coagulation necrosis for each treatment. Necrosis areas were measured as adapted from our previous reports [ 8 , 37 ], with a total of three sections (20 μm far) for each tumor collected from five mice per group.…”

Clinical and Experimental Effectiveness of Astragali Compound in the Treatment of Chronic Viral Hepatitis B

“…The treatment control group was given PN at a daily dose of 1.5 g. Both drugs were well mixed into the ducks' feed; half the daily dose was given in the morning and half in the evening for 2 months. 6 serum anti-HCV was determined by enzyme-linked immunosorbent assay (ELISA), serum HBV DNA was determined by polymerase chain reaction (PCR) 7 and serum HCV RNA was detected by reverse transcriptase (RT)-PCR. 8 Liver enzymes, including alanine transferase and serum bilirubin, were determined using an autobiochemical analysis machine (AU400; Olympus, Tokyo, Japan).…”